Menu Search
Equities

Ocumension Therapeutics

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5DG:MUN

Ocumension Therapeutics

Actions
  • Price (EUR)0.785
  • Today's Change0.00 / 0.00%
  • Shares traded--
  • 1 Year change+52.43%
  • Beta1.1414
Data delayed at least 15 minutes, as of Feb 16 2026 07:06 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Ocumension Therapeutics is a company primarily engaged in the research, development and commercialization of ophthalmic pharmaceuticals. The products primarily include OT-401 Yutiq fluocinolone intravitreal implant, OT-702 Boyoujing aflibercept intravitreous injection, OT-402 Visudyne, OT- 204 Ou Qin sodium hyaluronate eye drops and OT-305 Betoptic S betaxolol hydrochloride and others. The products are used to treat various anterior and posterior segment eye diseases, such as uveitis, fundus diseases, refractive correction, dry eye disease (DED), glaucoma and conjunctivitis. The Company primarily operates its business in the domestic market.

  • Revenue in HKD (TTM)615.81m
  • Net income in HKD-282.30m
  • Incorporated2018
  • Employees505.00
  • Location
    Ocumension TherapeuticsNo. 1858 Yinzhongnan RoadGuoxiang Subdistrict, Wuzhong DistrictSUZHOU KY1-1205ChinaCHN
  • Websitehttps://www.ocumension.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.